Pharmaceutical companies are incorporating payer/HTA needs into their clinical and commercial launch planning. This is becoming increasingly relevant as growing healthcare expenditure means payers are more stringent regarding the evidence needed to achieve patient access at a price that is acceptable to both the pharmaceutical company and the payer. A lack of early pricing and market access input can lead to clinical and economic evidence challenges during HTA submissions.
This study investigates the industry perspective on drivers and challenges for a successful launch from a pricing and market access perspective, and the areas that can be improved in future.
Read our findings here….(Pricing and market access launch excellence: key challenges)